Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 195

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

The functional mu opioid receptor (OPRM1) Asn40Asp variant predicts short-term response to nicotine replacement therapy in a clinical trial

Lerman, C, Wileyto, E P, Patterson, F, Rukstalis, M, Audrain-McGovern, J, Restine, S, Shields, P G, Kaufmann, V, Redden, D, Benowitz, N, Berrettini, W H·2004·The Pharmacogenomics Journal
DOI 10.1038/sj.tpj.6500238
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/sj.tpj.6500238

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Research works printed but not linked: 52

  1. USPHS. A clinical practice guideline for treating tobacco use and dependence. JAMA 2000; 283: 3244–3254. · DOI · Paper page
  2. Transdermal Nicotine Study Group. Transdermal nicotine for smoking cessation: six-month results from two multicenter controlled trials. JAMA 1991; 266: 3133–3138. · DOI
  3. Fiore M, Smith S, Jorenby D, Baker T . The effectiveness of the nicotine patch for smoking cessation. A meta-analysis. JAMA 1994; 271: 1940–1947. · DOI · Paper page
  4. Zadina JE, Hackler L, Ge LJ, Kastin AJ . A potent and selective endogenous agonist for the mu-opiate receptor. Nature 1997; 386: 499–502. · DOI · Paper page
  5. Boyadjieva NI, Sarkar DK . The secretory response of hypothalamic beta-endorphin neurons to acute and chronic nicotine treatments and following nicotine withdrawal. Life Sci 1997; 61: PL59–66. · DOI · Paper page
  6. Davenport KE, Houdi AA, Van Loon GR . Nicotine protects against mu-opioid receptor antagonism by beta-funaltrexamine: evidence for nicotine-induced release of endogenous opioids in brain. Neurosci Lett 1990; 113: 40–46. · DOI
  7. Bond LaForge K et al. Single nucleotide polymorphism in the human mu opioid receptor gene alters Beta-endorphin binding and activity: possible implications for opiate addiction. Proc Natl Acad Sci USA 1998; 95: 9608–9613. · DOI · Paper page
  8. Gelernter J, Kranzler H, Cubells J . Genetics of two mu opioid receptor gene (OPRM1) exon I polymorphisms: population studies, and allele frequencies in alcohol- and drug-dependent subjects. Mol Psychiatry 1999; 4: 476–483. · DOI · Paper page
  9. Crowley JJ et al. A genetic association study of the mu opioid receptor and severe opioid dependence. Psychiatr Genet 2003; 13: 169–173. · DOI
  10. Henningfield J, Keenan R . Nicotine delivery kinetics and abuse liability. J Consult Clin Psychol 1993; 61: 743–750. · DOI · Paper page
  11. Henningfield J . Nicotine medications for smoking cessation. N Engl J Med 1995; 333: 1196–1203. · DOI · Paper page
  12. Hughes J . Pharmacotherapy for smoking cessation: unvalidated assumptions, anomalies, and suggestions for future research. J Consult Clin Psychol 1993; 61: 751–760. · doi:10.1037/0022-006x.61.5.751
  13. Johansson CJ, Olsson P, Bende M, Carlsson T, Gunnarsson PO . Absolute bioavailability of nicotine applied to different nasal regions. Eur J Clin Pharmacol 1991; 41: 585–588. · DOI
  14. Benowitz N . Pharmacology of nicotine: addiction and therapeutics. Annu Rev Pharmacol Toxicol 1996; 36: 597–613. · DOI · Paper page
  15. Silagy C, Mant D, Fowler G, Lodge M . Meta-analysis on efficacy of nicotine replacement therapies in smoking cessation. Lancet 1994; 343: 139–142. · DOI · Paper page
  16. Tonnesen P, Norregaard J, Simonsen K, Sawe U . A double-blind trial of a 16-h transdermal nicotine patch in smoking cessation. N Engl J Med 1991; 325: 311–315. · DOI · Paper page
  17. Hjalmarson A, Franzon M, Westin A, Wiklund O . Effect of nicotine nasal spray on smoking cessation. A randomized, placebo-controlled, double-blind study. Arch Intern Med 1994; 154: 2567–2572. · DOI
  18. Wetter D et al. Gender differences in smoking cessation. J Counsel Clin Psychol 1999; 67: 555–562. · doi:10.1037/0022-006x.67.4.555 · Paper page
  19. Lerman C et al. Effects of dopamine transporter and receptor polymorphisms on smoking cessation in a bupropion clinical trial. Health Psychol 2003. · DOI
  20. Cardon LR, Palmer LJ . Population stratification and spurious allelic association. Lancet 2003; 361: 598–604. · DOI · Paper page
  21. Hurt RD et al. Nicotine patch therapy for smoking cessation combined with physician advice and nurse follow-up. One-year outcome and percentage of nicotine replacement. JAMA 1994; 271: 595–600. · DOI · Paper page
  22. Sachs DP, Sawe U, Leischow SJ . Effectiveness of a 16-h transdermal nicotine patch in a medical practice setting, without intensive group counseling. Arch Intern Med 1993; 153: 1881–1890. · DOI
  23. Gu DF, Hinks LJ, Morton NE, Day IN . The use of long PCR to confirm three common alleles at the CYP2A6 locus and the relationship between genotype and smoking habit. Ann Hum Genet 2000; 64: 383–390. · DOI
  24. Lerman C et al. Pharmacogenetic investigation of smoking cessation treatment. Pharmacogenetics 2002; 12: 627–634. · DOI · Paper page
  25. Lerman C et al. Effects of dopamine transporter and receptor polymorphisms on smoking cessation in a bupropion clinical trial. Health Psychol 2003; 22: 541–548. · DOI
  26. Houdi AA, Pierzchala K, Marson L, Palkovits M, Van Loon GR . Nicotine-induced alteration in Tyr–Gly–Gly and Met-enkephalin in discrete brain nuclei reflects altered enkephalin neuron activity. Peptides 1991; 12: 161–166. · DOI
  27. Pierzchala K, Houdi AA, Van Loon GR . Nicotine-induced alterations in brain regional concentrations of native and cryptic Met- and Leu-enkephalin. Peptides 1987; 8: 1035–1043. · DOI
  28. Wewers ME, Tejwani GA, Anderson J . Plasma nicotine, plasma beta-endorphin and mood states during periods of chronic smoking, abstinence and nicotine replacement. Psychopharmacology (Berl) 1994; 116: 98–102. · DOI
  29. Gilbert DG, Meliska CJ, Plath LC . Noise stress does not modulate effects of smoking/nicotine on beta-endorphin, cortisol, ACTH, glucose, and mood. Psychopharmacology (Berl) 1997; 130: 197–202. · DOI
  30. Pomerleau OF, Fertig JB, Seyler LE, Jaffe J . Neuroendocrine reactivity to nicotine in smokers. Psychopharmacology (Berl) 1983; 81: 61–67. · DOI · Paper page
  31. Spanagel R, Herz A, Bals-Kubik R, Shippenberg TS . Beta-endorphin-induced locomotor stimulation and reinforcement are associated with an increase in dopamine release in the nucleus accumbens. Psychopharmacology (Berl) 1991; 104: 51–56. · DOI
  32. Low MJ, Hayward MD, Appleyard SM, Rubinstein M . State-dependent modulation of feeding behavior by proopiomelanocortin-derived beta-endorphin. Ann NY Acad Sci 2003; 4: 192–201. · DOI
  33. Appleyard SM et al. A role for the endogenous opioid beta-endorphin in energy homeostasis. Endocrinology 2003; 4: 1753–1760. · DOI
  34. Radcliffe RA, Erwin VG . Genetic relationship between central beta-endorphin and novelty-induced locomotor activity. Pharmacol Biochem Behav 1998; 60: 709–718. · doi:10.1016/s0091-3057(98)00045-8
  35. Jorenby D et al. Varying nicotine patch dose and type of smoking cessation counseling. JAMA 1995; 274: 1347–1352. · DOI · Paper page
  36. Tonnesen P et al. Higher dosage nicotine patches increase one-year smoking cessation rates: results from the European CEASE trial. Collaborative European Anti-Smoking Evaluation. European Respiratory Society. Eur Respir J 1999; 13: 238–246. · DOI
  37. Pomerleau OF et al. Prolonged nicotine patch use in quitters with past abstinence-induced depressed mood. J Subst Abuse Treat 2003; 24: 13–18. · DOI
  38. Magura S, Rosenblum A . Leaving methadone treatment: lessons learned, lessons forgotten, lessons ignored. Mt Sinai J Med 2001; 68: 62–74.
  39. Ahluwalia JS, McNagny SE, Clark WS . Smoking cessation among inner-city African Americans using the nicotine transdermal patch. J Gen Intern Med 1998; 13: 1–8. · DOI
  40. Perng RP, Hsieh WC, Chen YM, Lu CC, Chiang SJ . Randomized, double-blind, placebo-controlled study of transdermal nicotine patch for smoking cessation. J Formos Med Assoc 1998; 97: 547–551.
  41. Xu C, Goodz S, Sellers EM, Tyndale RF . CYP2A6 genetic variation and potential consequences. Adv Drug Deliv Rev 2002; 54: 1245–1256. · DOI
  42. Sutherland G et al. Randomised controlled trial of nasal nicotine spray in smoking cessation. Lancet 1992; 340: 324–329. · DOI · Paper page
  43. Fiore MC et al. Two studies of the clinical effectiveness of the nicotine patch with different counseling treatments. Chest 1994; 105: 524–533. · DOI
  44. Brown R, Burgess E, Sales S, Whiteley J . Reliability and validity of a smoking timeline follow-back interview. Psychol Addictive Behav 1998; 12: 101–112. · DOI · Paper page
  45. Hughes JR et al. Measure of abstinence in clinical trials: issues and recommendations. Nicotine Tobacco Res 2003; 5: 13–25. · DOI · Paper page
  46. Ossip-Klein DJ et al. Classification and assessment of smoking behavior. Health Psychol 1986; 5(Suppl): 3–11. · DOI
  47. Hosmer DW, Lemeshow S . Applied Survival Analysis: Regression Modeling of Time to Event Data. John Wiley & Sons: New York, NY 1999.
  48. Lawson GM et al. Application of serum nicotine and plasma cotinine concentrations to assessment of nicotine replacement in light, moderate, and heavy smokers undergoing transdermal therapy. J Clin Pharmacol 1998; 38: 502–509. · DOI
  49. Jacob III P, Wilson M, Benowitz NL . Improved gas chromatographic method for the determination of nicotine and cotinine in biologic fluids. J Chromatogr 1981; 222: 61–70. · DOI · Paper page
  50. Watson D, Clark L, Tellegen A . Development and validation of brief measures of positive and negative affect: the PANAS scales. J Personality Social Psychol 1988; 54: 1063–1070. · DOI · Paper page
  51. Long JC, Williams RC, Urbanek M . An E-M algorithm and testing strategy for multiple-locus haplotypes. Am J Hum Genet 1995; 56: 799–810.
  52. Mander A . Haplotype analysis in population-based association studies. Stata J 2001; 1: 58–75. · DOI

Cited by

See all 195

Metadata

Authors
Lerman, C., Wileyto, E. P., Patterson, F., Rukstalis, M., Audrain-McGovern, J., Restine, S., Shields, P. G., Kaufmann, V, Redden, D., Benowitz, N., & Berrettini, W. H.
Venue
The Pharmacogenomics Journal
Publisher
Springer Science and Business Media LLC
Published
2004-03-09
Volume
4
Issue
3
Pages
184-192
ISSN
  • 1470-269X (ISSN-L)
  • 1473-1150
DOI
10.1038/sj.tpj.6500238
OpenAlex
W1966042288
Cited by
195
References
5
FWCI
12.35
Type
journal article
Language
en
Open access
closed
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The functional mu opioid receptor (OPRM1) Asn40Asp variant predicts short-term response to nicotine replacement therapy in a clinical trial. https://app.cochat.ai/papers/10.1038/sj.tpj.6500238
The paper
Lerman, C., Wileyto, E. P., Patterson, F., Rukstalis, M., Audrain-McGovern, J., Restine, S., Shields, P. G., Kaufmann, V, Redden, D., Benowitz, N., & Berrettini, W. H. (2004). The functional mu opioid receptor (OPRM1) Asn40Asp variant predicts short-term response to nicotine replacement therapy in a clinical trial. The Pharmacogenomics Journal. https://doi.org/10.1038/sj.tpj.6500238

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.